Deulorlatinib

N/A

Report date: 2026/04/03 20:03:44
NME

Base Information

Drug NameDeulorlatinib
Drug Alias NameTGRX-326
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAnaplastic lymphoma kinase inhibitorsProto-oncogene tyrosine-protein kinase ROS modulators
TargetsAnaplastic lymphoma kinaseProto-oncogene tyrosine-protein kinase ROS
Therapy Area/IndicationsCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesShenzhen TargetRx Inc
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesShenzhen TargetRx Inc
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell Lung
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A